Cancer in Transgender People: Evidence and Methodological Considerations.

IF 5.2 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Epidemiologic Reviews Pub Date : 2017-01-01 DOI:10.1093/epirev/mxw003
Hayley Braun, Rebecca Nash, Vin Tangpricha, Janice Brockman, Kevin Ward, Michael Goodman
{"title":"Cancer in Transgender People: Evidence and Methodological Considerations.","authors":"Hayley Braun, Rebecca Nash, Vin Tangpricha, Janice Brockman, Kevin Ward, Michael Goodman","doi":"10.1093/epirev/mxw003","DOIUrl":null,"url":null,"abstract":"<p><p>Transgender people comprise a diverse group of individuals whose gender identity or expression differs from that originally assigned to them at birth. Some, but not all, transgender people elect to undergo medical gender affirmation, which may include therapy with cross-sex hormones and/or surgical change of the genitalia and other sex characteristics. As cross-sex hormones administered for the purposes of gender affirmation may be delivered at high doses and over a period of decades, the carcinogenicity of hormonal therapy in transgender people is an area of considerable concern. In addition, concerns about cancer risk in transgender patients have been linked to sexually transmitted infections, increased exposure to well-known risk factors such as smoking and alcohol use, and the lack of adequate access to screening. Several publications have identified cancer as an important priority in transgender health research and called for large-scale studies. The goals of this article are to summarize the evidence on factors that may differentially affect cancer risk in transgender people, assess the relevant cancer surveillance and epidemiologic data available to date, and offer an overview of possible methodological considerations for future studies investigating cancer incidence and mortality in this population.</p>","PeriodicalId":50510,"journal":{"name":"Epidemiologic Reviews","volume":null,"pages":null},"PeriodicalIF":5.2000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868281/pdf/mxw003.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/epirev/mxw003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Transgender people comprise a diverse group of individuals whose gender identity or expression differs from that originally assigned to them at birth. Some, but not all, transgender people elect to undergo medical gender affirmation, which may include therapy with cross-sex hormones and/or surgical change of the genitalia and other sex characteristics. As cross-sex hormones administered for the purposes of gender affirmation may be delivered at high doses and over a period of decades, the carcinogenicity of hormonal therapy in transgender people is an area of considerable concern. In addition, concerns about cancer risk in transgender patients have been linked to sexually transmitted infections, increased exposure to well-known risk factors such as smoking and alcohol use, and the lack of adequate access to screening. Several publications have identified cancer as an important priority in transgender health research and called for large-scale studies. The goals of this article are to summarize the evidence on factors that may differentially affect cancer risk in transgender people, assess the relevant cancer surveillance and epidemiologic data available to date, and offer an overview of possible methodological considerations for future studies investigating cancer incidence and mortality in this population.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
变性人的癌症:证据和方法论考虑。
变性人是一个多样化的群体,他们的性别认同或性别表达方式与出生时最初被赋予的性别不 同。一些变性人(但并非所有变性人)选择接受医学性别确认,这可能包括使用异性荷尔蒙治疗和/或改变生殖器和其他性特征的手术。由于以确认性别为目的的跨性别荷尔蒙可能会在数十年内以高剂量施用,因此变性人接受荷尔蒙治疗的致癌性是一个相当令人担忧的领域。此外,对变性人患癌风险的担忧还与性传播感染、吸烟和酗酒等众所周知的风险因素的增加以及缺乏适当的筛查机会有关。一些出版物已将癌症确定为变性人健康研究的一个重要优先事项,并呼吁进行大规模研究。本文旨在总结可能对变性人患癌风险产生不同影响的因素的证据,评估迄今为止可用的相关癌症监测和流行病学数据,并概述未来调查该人群癌症发病率和死亡率的研究可能需要考虑的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Epidemiologic Reviews
Epidemiologic Reviews 医学-公共卫生、环境卫生与职业卫生
CiteScore
8.10
自引率
0.00%
发文量
10
期刊介绍: Epidemiologic Reviews is a leading review journal in public health. Published once a year, issues collect review articles on a particular subject. Recent issues have focused on The Obesity Epidemic, Epidemiologic Research on Health Disparities, and Epidemiologic Approaches to Global Health.
期刊最新文献
A systematic review of lethal means safety counseling interventions: impacts on safety behaviors and self-directed violence. Instruments for racial health equity: a scoping review of structural racism measurement, 2019-2021. A review of the epidemiology of invasive fungal infections in Asian patients with hematological malignancies (2011-2021). The effect of post-traumatic chondropathy on the functional state of knee joints in athletes during the basketball game. The measurement of racism in health inequities research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1